300Microns

Executive Summary

300Microns GmbH is a German biotechnology company specializing in flexible 3D cell culture solutions based on proprietary polymer film-based microwell arrays. Spin-off from the Karlsruhe Institute of Technology (KIT), the company manufactures and markets products for culturing spheroids, organoids, and other 3D cellular aggregates. Its technology targets academic research, industrial R&D, screening, and production applications, and it also offers custom OEM solutions. Founded in 2018 and headquartered in Munich, 300Microns operates in the drug delivery and medical devices sectors, addressing the growing demand for physiologically relevant in vitro models. While the company has not disclosed funding or valuation, its innovative platform positions it well in the 3D cell culture market, which is expanding due to the shift away from 2D models in drug discovery and regenerative medicine.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Round60% success
• Q2 2027Strategic Partnership with Major Pharma40% success
• Q3 2026Launch of Next-Generation Microwell Array Product70% success